Bright Minds Biosciences Inc.

DRUG is overvalued

NASDAQ · Healthcare

FAIR PRICE

71.9%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

$50.44

MARKET PRICE

$14.17

FAIR PRICE

$36.27

MARGIN

UNDERFAIROVER

COMMUNITY BUY ZONE

UNLOCKS AT 10

Where does the market buy DRUG?

No one has priced DRUG yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.

COMMUNITY MEDIAN

▓▓▓▓▓

BUYERS AT TODAY'S PRICE

▓▓ %

0/10 INVESTORS · 10 MORE TO UNLOCK

SET YOUR PRICE — iOS →ANDROID →

METRICS

P/E–

P/B–

P/S–

PEG–

DIV YIELD–

EV/EBITDA–

ROE–

ROIC–

NET MARGIN–

DEBT/EQ–

FCF YIELD–

MKT CAPN/A

NOW AVAILABLE

Get notified when DRUG's fair price changes

Push notifications when DRUG's valuation shifts. Available on iOS and Android.

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$11.34CONSERVATIVE ENTRY

$14.17FAIR PRICE

$50.44MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$11.34

Fair price × 0.80

DISTANCE

77.5%

Price to entry level

At the current price of $50.44, DRUG trades 77.5% above the conservative entry level of $11.34. This entry level represents a 20% margin of safety below the calculated fair price of $14.17 — a buffer that accounts for estimation uncertainty in the valuation model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

SYNCING FEED ▌

P/E RATIO HISTORY

SYNCING FEED ▌

METHODOLOGY

How we calculate DRUG's fair price

Bright Minds Biosciences Inc.'s fair price of $14.17 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $50.44, DRUG trades 71.9% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting DRUG's risk profile.

RELATIVE · 30%

Comparing DRUG's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for DRUG, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate DRUG's fair value with your own inputs.

CALCULATOROpen →

DRUG DCF Calculator

Pre-filled with DRUG's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.

CALCULATOROpen →

Graham Number

Enter DRUG's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.

CALCULATOROpen →

P/E Ratio Calculator

Check how much investors pay per dollar of DRUG's earnings and compare it against sector benchmarks.

CALCULATOROpen →

EV/EBITDA Calculator

Compare DRUG against peers on a debt-adjusted basis using enterprise value and EBITDA.

LEARN MORE

What Is Fair Value?

How fair price is calculated and why it matters.

P/E Ratio Explained

What the price-to-earnings ratio tells you.

Margin of Safety

Warren Buffett's key investing principle.

Get full analysis, financials, and AI insights for DRUG.

Explore on Bulios

FAQ

What is the fair price of DRUG?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Bright Minds Biosciences Inc. is $14.17. At the current market price of $50.44, DRUG trades 71.9% above its calculated fair value.

Is DRUG overvalued or undervalued?+

Bright Minds Biosciences Inc. is currently overvalued based on our valuation model. The stock trades at $50.44, which is 71.9% above the fair price of $14.17.

What is the margin of safety for DRUG?+

With a 20% margin of safety applied to the fair price of $14.17, the conservative entry level for DRUG is $11.34. At the current market price of $50.44, the stock trades 77.5% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is DRUG's fair price updated?+

We update fair price calculations for DRUG daily after market close. The current fair price of $14.17 incorporates the latest market data and sector multiples.

What factors affect DRUG's fair price calculation?+

DRUG's fair price of $14.17 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)..

Is DRUG a good buy right now?+

At $50.44, DRUG trades 71.9% above our fair value estimate of $14.17. The stock is currently overvalued. Fair Price Index provides valuation data — always do your own research before investing.

Does DRUG pay dividends?+

DRUG does not currently pay a dividend.

RELATED STOCKS

Pfizer

Novo Nordisk

Johnson & Johnson

CVS

All healthcare stocks vs fair value →Today's most undervalued stocks →

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.